1Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
© 2020 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Author Contributions
Conceptualization: KJC.
Data curation: ML, KJC.
Formal analysis: ML, KJC.
Funding acquisition: KJC, SMH.
Investigation: ML, KJC.
Methodology: ML, KJC.
Project administration: ML.
Resources: JSS, SMH, SJJ, JK, KBS, JHL, KJC.
Supervision: KJC.
Validation: ML, KJC.
Visualization: ML.
Writing—original draft: ML, KJC.
Writing—review & editing: ML, KJC.
Conflicts of Interest
The authors declare that they have no potential conflicts of interest.
Funding
No funding to declare.
F, female; OP, operation; FNCLCC, Fédération Nationale des Centres de Lutte Contre le Cancer; NeoCTx, neoadjuvant chemotherapy; DP, distal pancreatectomy; M, male; RTx, radiation therapy; CTx, adjuvant chemotherapy; T, tumorectomy; WHO, World Health Organization; NA, not available; PPPD, pylorus-preserving pancreaticoduodenectomy; LN, lymph node.
Case No. | Sex/age at pancreatic metastasis (yr) | Primary tumor |
Pathologic diagnosis | Interval between primary tumor detection and pancreatic metastasis (mo) | Pancreatic metastasis |
Associated metastases | Survival after pancreatic metastasis (mo) |
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Location | Size (cm) | Treatment | Local recurrence | Location | No. of pancreatic metastases | Size (largest, cm) | Treatment | Type of procedure | Dead | Alive | |||||
1 | F/62 | Lung | 7.5 | OP | No | Synovial sarcoma, FNCLCC grade 3 | 40 | Body | Single | 2.7 | NeoCTx + OP | DP | No | - | 92 |
2 | M/45 | Lung | 7 | OP | Yes | Malignant solitary fibrous tumor, FNCLCC grade 3 | 11 | Tail | Single | 2.6 | OP + RTx and CTx | T | Umbilicus, adrenal gland | 24 | - |
3 | F/48 | Brain | 7.5 | OP + RTx | Yes | Solitary fibrous tumor/ hemangiopericytoma, WHO grade III | 64 | Body, tail | Multiple | 3.5 | RTx + OP | DP | Bone (femur, tibia), breast, lung | 31 | - |
4 | F/70 | Brain | NA | OP + RTx | Yes | Solitary fibrous tumor/ hemangiopericytoma, WHO grade III | 135 | Head | Single | 2.6 | OP + RTx | PPPD | Bone (humerus), lung, | - | 41 |
5 | F/58 | Bone (tibia) | 6 | NeoCTx + OP + CTx | No | Undifferentiated pleomorphic sarcoma, FNCLCC grade 3 | 88 | Head | Single | 3.5 | RTx + CTx | Biopsy | Bone (pelvis) | - | 10 |
6 | F/57 | Bone (femur) | 9 | OP + RTx + CTx | No | Osteosarcoma, FNCLCC grade 3 | 15 mo prior | Tail | Single | 2.7 | OP + CTx | DP | Skin (scalp), bone (rib, ilium, sternum, pelvis), brain | 18 | - |
7 | F/32 | Bone (skull) | 4 | OP + RTx | No | Mesenchymal chondrosarcoma, FNCLCC grade 3 | 65 | Tail | Single | 19 | OP | DP | Lung, mesentery, bone (femur) | 48 | - |
8 | F/28 | Bone (femur) | 11.7 | NeoCTx + OP + CTx | No | High-grade spindle-cell sarcoma, type uncertain, FNCLCC grade 3 | 20 | Body | Single | 4 | OP | DP | Bone (pelvis) | 11 | - |
9 | F/35 | Pulmonary vein | 4.6 | RTx + OP | Yes | Intimal sarcoma, FNCLCC grade 2 | 14 | Tail | Single | 2.6 | CTx | Biopsy | Retroperitoneal LN, bone (left humerus), lung | 29 | - |
10 | M/52 | Soft tissue (knee) | 8.2 | OP + RTx + CTx | No | Myxofibrosarcoma, FNCLCC grade 2 | 26 | Head | Single | 2.5 | OP | PPPD | No | - | 4 |
11 | M/35 | Soft tissue (thigh) | 22 | OP | No | Myxoid liposarcoma, FNCLCC grade 2 | 0 | Tail | Multiple | 11 | OP + CTx | DP | Bone (humerus) | 16 | - |
12 | F/60 | Uterus | 8.5 | OP | Yes (vaginal stump) | Rhabdomyosarcoma, subtype uncertain, FNCLCC grade 3 | 8 | Head, body, tail | Multiple | NA | CTx | Biopsy | No | 5 | - |
F, female; OP, operation; FNCLCC, Fédération Nationale des Centres de Lutte Contre le Cancer; NeoCTx, neoadjuvant chemotherapy; DP, distal pancreatectomy; M, male; RTx, radiation therapy; CTx, adjuvant chemotherapy; T, tumorectomy; WHO, World Health Organization; NA, not available; PPPD, pylorus-preserving pancreaticoduodenectomy; LN, lymph node.